VERVE-201

Verve Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	VERVE-201
Sponsor	Verve Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VERVE-201 CI brief — competitive landscape report
VERVE-201 updates RSS · CI watch RSS
Verve Therapeutics, Inc. portfolio CI